What is the recommended dosage of atomoxetine (Strattera) for an adult patient with Attention Deficit Hyperactivity Disorder (ADHD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 29, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Atomoxetine Adult Dosage

For adults with ADHD, start atomoxetine at 40 mg once daily in the morning, then titrate to the target dose of 80 mg daily after a minimum of 3 days, with a maximum dose of 100 mg/day. 1, 2

Initial Dosing Strategy

  • Begin with 40 mg orally once daily in the early morning for all adults and patients weighing over 70 kg 1, 2
  • After a minimum of 3 days at the initial dose, increase to the target dose of 80 mg daily 1
  • The 80 mg dose can be administered either as a single morning dose or divided into two doses (early morning and late afternoon/early evening) 1, 2

Titration Schedule

  • Increase the dose every 7-14 days based on clinical response and tolerability, following the sequence: 40 mg → 60 mg → 80 mg daily 1
  • The target dose of 1.2 mg/kg/day demonstrates equivalent efficacy to higher doses without additional benefit 1
  • Maximum recommended dose is 100 mg/day or 1.4 mg/kg/day, whichever is lower 1, 2, 3

Critical Timing Considerations

Atomoxetine requires 6-12 weeks to achieve full therapeutic effect, unlike stimulants which work within days—this is essential for setting appropriate patient expectations 4

  • Maintain patients at the target dose for at least 4-6 weeks before judging efficacy, as premature dose adjustments or discontinuation due to perceived lack of response is a common pitfall 5
  • Initial somnolence and gastrointestinal symptoms are particularly common if dosage is increased too rapidly 1

Dosing Flexibility

  • Once-daily morning dosing is effective and may improve adherence as an alternative to divided dosing 1, 6
  • Both once-daily (80 mg QD) and twice-daily (40 mg BID) strategies are safe, well-tolerated, and efficacious, though nausea frequency is significantly lower with BID dosing (16.4% vs 32.4%, p=0.007) 6
  • Prescribers have discretion to base dosing strategies on individual factors, particularly gastrointestinal tolerability 6

Common Pitfall: Underdosing

Real-world data show that an average adult atomoxetine dose of only 60 mg/day is commonly utilized, despite the 80 mg/day target dose recommendation—this suboptimal dosing may be associated with poor patient outcomes 5

  • The most common adverse effects include nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence 1, 7
  • Slow titration (increasing dose gradually every 1-2 weeks) is generally better tolerated and helps avoid unintentionally exceeding the optimal medication dose 4

Special Populations and Drug Interactions

  • SSRIs can elevate serum atomoxetine levels through CYP2D6 inhibition, potentially requiring dose adjustment in patients taking both medications 8, 1
  • Approximately 7% of the population are poor CYP2D6 metabolizers with significantly higher plasma levels and longer half-lives, leading to increased adverse effects 1
  • Atomoxetine can be administered to patients with end-stage renal disease using the normal dosing regimen, as dose-corrected exposure is similar to healthy subjects 2

Safety Monitoring Requirements

  • Monitor closely for suicidal ideation, clinical worsening, and unusual behavioral changes, especially during the first few months of treatment or at dose changes, due to FDA black box warning 8, 1
  • Monitor heart rate and blood pressure at baseline and regularly during treatment, as atomoxetine may increase both parameters 1
  • Behavioral activation/agitation (including motor or mental restlessness, insomnia, impulsiveness, aggression) can occur early in treatment or with dose increases 4

References

Guideline

Atomoxetine Dosage and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004

Guideline

Risks of Increasing Strattera Dosage

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD.

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2006

Guideline

Medication Options for Managing Both Mood Symptoms and ADHD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.